A novel adenoviral vector armed with human osteonectin promoter driven PML inhibits human renal cell carcinoma growth
碩士 === 中國醫藥大學 === 癌症生物學研究所碩士班 === 101 === Introduction: Advanced renal cell carcinoma (RCC) is highly resistant to conventional therapies. Patients with advanced RCC have an extremely poor outcome with an estimated median survival of less than 1 year. It is medically urgent to develop new therapies...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2013
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/37628024045216584832 |